Drug intelligence / Profile preview

CyDerm002

Development stage: Preclinical
Lead developer: RION
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

CyDerm002 is a preclinical-stage exosome-based drug delivery system developed by RION. It utilizes the company's proprietary PEP™ (Purified Exosome Product) platform, which consists of platelet-derived exosomes. CyDerm002 is specifically engineered to serve as a delivery vehicle for chemotherapeutic agents, leveraging the natural biological properties and uptake mechanisms of exosomes to transport toxic cargo directly to target tissues. By encapsulating chemotherapy drugs within platelet-derived exosomes, the system aims to improve the therapeutic index of cancer treatments by enhancing targeted delivery and potentially reducing systemic off-target toxicities.

Other names: CyDerm002-RION-exosome drug delivery-PEP™-Chemotherapy delivery

Beyond the preview

Go deeper on CyDerm002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CyDerm002.

Explore the full profile